M H Horellou|M Samama - JoVE Visualize

Showing results (21-30 of 426) with videos related to

Pageof 43

Sort By:

Journal Des Maladies Vasculaires|January 1, 1987

[Biological modifications induced by 3 low molecular weight heparins, PK 10169, Kabi 2165 and CY 216, compared to unfractionated heparin injected subcutaneously in healthy subjects in general surgery and in aged subjects in internal medicine]L Bara, S Combe-Tamzali, J Conard, et al.

Annals of Medicine|February 24, 2001

Heparin-induced thrombocytopenia: laboratory diagnosis and managementI Elalamy, C Lecrubier, M H Horellou, et al.

Journal Des Maladies Vasculaires|January 1, 1995

[Hemorrhagic complications of anti-vitamin K treatments]S Bentolila, S Radenne, M H Horellou, et al.

Haemostasis|January 1, 1987

Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest)L Bara, S Combe-Tamzali, J Conard, et al.

Annales De Medecine Interne|January 1, 1988

[Acquired factor VII inhibitor: treatment using high-dose immunoglobulins, corticotherapy and plasma exchange]A Delmer, G Andreu, M H Horellou, et al.

Journal Des Maladies Vasculaires|January 1, 1987

[Platelet aggregation tests in 26 cases of heparin-induced thrombopenia. Methodological, diagnostic problems and therapeutic aspects]C Lecrubier, T Lecompte, F Potevin, et al.

International Angiology : a Journal of the International Union of Angiology|May 22, 2004

Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episodeE Ombandza-Moussa, M M Samama, M H Horellou, et al.

Blood|August 1, 1988

Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosisG Nguyen, M H Horellou, E K Kruithof, et al.

Thrombosis and Haemostasis|July 31, 1998

Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparinP Toulon, B Boutière, M H Horellou, et al.

Presse Medicale (Paris, France : 1983)|June 14, 1997

[Multigenic thrombophilia: genetic anomaly of factor II and mutation of factor V Leiden. Study in a French family]J Conard, C Mabileau-Brouzes, M H Horellou, et al.

Pageof 43

Showing results (21-30 of 426) with videos related to

Sort By:

Pageof 43

Journal Des Maladies Vasculaires|January 1, 1987

[Biological modifications induced by 3 low molecular weight heparins, PK 10169, Kabi 2165 and CY 216, compared to unfractionated heparin injected subcutaneously in healthy subjects in general surgery and in aged subjects in internal medicine]L Bara, S Combe-Tamzali, J Conard, et al.

Annals of Medicine|February 24, 2001

Heparin-induced thrombocytopenia: laboratory diagnosis and managementI Elalamy, C Lecrubier, M H Horellou, et al.

Journal Des Maladies Vasculaires|January 1, 1995

[Hemorrhagic complications of anti-vitamin K treatments]S Bentolila, S Radenne, M H Horellou, et al.

Haemostasis|January 1, 1987

Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest)L Bara, S Combe-Tamzali, J Conard, et al.

Annales De Medecine Interne|January 1, 1988

[Acquired factor VII inhibitor: treatment using high-dose immunoglobulins, corticotherapy and plasma exchange]A Delmer, G Andreu, M H Horellou, et al.

Journal Des Maladies Vasculaires|January 1, 1987

[Platelet aggregation tests in 26 cases of heparin-induced thrombopenia. Methodological, diagnostic problems and therapeutic aspects]C Lecrubier, T Lecompte, F Potevin, et al.

International Angiology : a Journal of the International Union of Angiology|May 22, 2004

Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episodeE Ombandza-Moussa, M M Samama, M H Horellou, et al.

Blood|August 1, 1988

Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosisG Nguyen, M H Horellou, E K Kruithof, et al.

Thrombosis and Haemostasis|July 31, 1998

Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparinP Toulon, B Boutière, M H Horellou, et al.

Presse Medicale (Paris, France : 1983)|June 14, 1997

[Multigenic thrombophilia: genetic anomaly of factor II and mutation of factor V Leiden. Study in a French family]J Conard, C Mabileau-Brouzes, M H Horellou, et al.

Pageof 43